Cantitate/Preț
Produs

Quantitative Evaluation of Safety in Drug Development: Design, Analysis and Reporting: Chapman & Hall/CRC Biostatistics Series

Editat de Qi Jiang, H. Amy Xia
en Limba Engleză Paperback – 30 iun 2020
State-of-the-Art Methods for Drug Safety Assessment




Responding to the increased scrutiny of drug safety in recent years, Quantitative Evaluation of Safety in Drug Development: Design, Analysis and Reporting explains design, monitoring, analysis, and reporting issues for both clinical trials and observational studies in biopharmaceutical product development. It presents the latest statistical methods for drug safety assessment.




The book’s three sections focus on study design, safety monitoring, and data evaluation/analysis. The book addresses key challenges across regulatory agencies, industry, and academia. It discusses quantitative approaches to safety evaluation and risk management in drug development, covering Bayesian methods, effective safety graphics, and risk-benefit evaluation.




Written by a team of experienced leaders, this book brings the most advanced knowledge and statistical methods of drug safety to the statistical, clinical, and safety community. It shares best practices and stimulates further research and methodology development in the drug safety area.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 31196 lei  6-8 săpt.
  CRC Press – 30 iun 2020 31196 lei  6-8 săpt.
Hardback (1) 77435 lei  6-8 săpt.
  CRC Press – 8 dec 2014 77435 lei  6-8 săpt.

Din seria Chapman & Hall/CRC Biostatistics Series

Preț: 31196 lei

Preț vechi: 35663 lei
-13% Nou

Puncte Express: 468

Preț estimativ în valută:
5970 6202$ 4959£

Carte tipărită la comandă

Livrare economică 01-15 februarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780367576004
ISBN-10: 0367576007
Pagini: 382
Dimensiuni: 156 x 234 mm
Greutate: 0.45 kg
Ediția:1
Editura: CRC Press
Colecția Chapman and Hall/CRC
Seria Chapman & Hall/CRC Biostatistics Series


Cuprins

Study Design. Safety Monitoring. Evaluation/Analysis. Index.

Notă biografică

Qi Jiang, PhD, is an executive director of Global Biostatistical Science at Amgen Inc. Dr. Jiang is a fellow of the American Statistical Association, a member of many industry-wide initiatives, and an associate editor of the journal Statistics in Biopharmaceutical Research (SBR). She has over 18 years of clinical trial experience in early and late clinical development phases across a broad spectrum of therapeutic areas. Her research interests include drug safety monitoring and analyses, benefit-risk assessment, clinical meaningfulness, dichotomization, meta-analyses, network meta-analysis, adaptive design, and non-inferiority study design and analyses.


H. Amy Xia, PhD, is an executive director of Global Biostatistical Science at Amgen Inc. Dr. Xia is a member of many industry-wide initiatives. In the past 18 years, she has worked on designing, executing, and reporting clinical trials as well as observational studies for developing pharmaceutical and medical device products in a wide range of different disease areas. Her research interests include safety biostatistics, signal detection, Bayesian design, monitoring and analysis of clinical trials, meta-analysis, and adaptive design.

Descriere

Written by a team of experienced leaders, this book brings the most advanced knowledge and statistical methods of drug safety to the statistical, clinical, and safety community. It explains design, monitoring, analysis, and reporting issues for both clinical trials and observational studies in biopharmaceutical product development. The book addr